These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23028040)

  • 1. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer.
    Aggarwal C; Meropol NJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse MA; Mitchell E; Miller MC; Cohen SJ
    Ann Oncol; 2013 Feb; 24(2):420-428. PubMed ID: 23028040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
    Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
    Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers for the early detection of relapses in metastatic colorectal cancers.
    Chereches G; Barbos O; Buiga R; Balacescu O; Iancu D; Todor N; Balacescu L; Miron N; Bejinariu N; Ciuleanu TE
    J BUON; 2017; 22(3):658-666. PubMed ID: 28730771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly Correlated Recurrence Prognosis in Patients with Metastatic Colorectal Cancer by Synergistic Consideration of Circulating Tumor Cells/Microemboli and Tumor Markers CEA/CA19-9.
    Chu HY; Yang CY; Yeh PH; Hsu CJ; Chang LW; Chan WJ; Lin CP; Lyu YY; Wu WC; Lee CW; Wu JK; Jiang JK; Tseng FG
    Cells; 2021 May; 10(5):. PubMed ID: 34068719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer.
    Prager GW; Braemswig KH; Martel A; Unseld M; Heinze G; Brodowicz T; Scheithauer W; Kornek G; Zielinski CC
    Cancer Sci; 2014 Aug; 105(8):996-1001. PubMed ID: 24850362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients.
    Shimada R; Iinuma H; Akahane T; Horiuchi A; Watanabe T
    Oncol Rep; 2012 Apr; 27(4):947-53. PubMed ID: 22267181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC).
    Sefrioui D; Beaussire L; Gillibert A; Blanchard F; Toure E; Bazille C; Perdrix A; Ziegler F; Gangloff A; Hassine M; Elie C; Bignon AL; Parzy A; Gomez P; Thill C; Clatot F; Sabourin JC; Frebourg T; Benichou J; Bouhier-Leporrier K; Gallais MP; Sarafan-Vasseur N; Michel P; Di Fiore F
    Br J Cancer; 2021 Aug; 125(5):725-733. PubMed ID: 34112948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients.
    Wang L; Zhou S; Zhang W; Wang J; Wang M; Hu X; Liu F; Zhang Y; Jiang B; Yuan H
    Int J Colorectal Dis; 2019 Apr; 34(4):589-597. PubMed ID: 30627849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
    Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse M; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
    J Clin Oncol; 2008 Jul; 26(19):3213-21. PubMed ID: 18591556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer.
    Messaritakis I; Sfakianaki M; Papadaki C; Koulouridi A; Vardakis N; Koinis F; Hatzidaki D; Georgoulia N; Kladi A; Kotsakis A; Souglakos J; Georgoulias V
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):767-775. PubMed ID: 30094617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?
    Gazzaniga P; Raimondi C; Gradilone A; Biondi Zoccai G; Nicolazzo C; Gandini O; Longo F; Tomao S; Lo Russo G; Seminara P; Vincenzi B; Chimenti I; Cristofanilli M; Frati L; Cortesi E
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1411-6. PubMed ID: 23736274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
    Yang C; Zou K; Zheng L; Xiong B
    BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and Therapeutic Significance of Circulating Tumor Cell Phenotype Detection Based on Epithelial-Mesenchymal Transition Markers in Early and Midstage Colorectal Cancer First-Line Chemotherapy.
    Lu G; Lu Z; Li C; Huang X; Luo Q
    Comput Math Methods Med; 2021; 2021():2294562. PubMed ID: 34777560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.
    Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse MA; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
    Ann Oncol; 2009 Jul; 20(7):1223-9. PubMed ID: 19282466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of CD133
    Fang C; Fan C; Wang C; Huang Q; Meng W; Yu Y; Yang L; Hu J; Li Y; Mo X; Zhou Z
    Cancer Med; 2017 Dec; 6(12):2850-2857. PubMed ID: 29105339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer.
    Pesta M; Fichtl J; Kulda V; Topolcan O; Treska V
    Anticancer Res; 2013 May; 33(5):2239-43. PubMed ID: 23645782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic diagnostic value of circulating tumor cells and tumor markers CEA/CA19-9 in colorectal cancer.
    Cai M; He H; Hong S; Weng J
    Scand J Gastroenterol; 2023 Jan; 58(1):54-60. PubMed ID: 35968572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.